Affini-T Therapeutics secures funding to advance T cell therapies
Affini-T has raised $175m in an oversubscribed financing round for advancing T cell therapies for solid tumour patients with oncogenic driver mutations.
📰 Erasca Ventures News
Erasca Ventures News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Erasca Ventures. Real-time updates on events, politics, business and more.
Affini-T Therapeutics Closes $175M Financing
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
United States Fred Hutchinson Cancer Research Center Al Iskandariyah Fred Hutch David Kranz Rafi Ahmed
Source: finsmes.com
Affini-T Therapeutics, Inc.: Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations
Co-founded at Fred Hutchinson Cancer Research Center with Phil Greenberg, M.D., Aude Chapuis, M.D., and Tom Schmitt, Ph.D., and Vida Ventures along with serial entrepreneurs Arjun Goyal, M.D., M.Phil.
United States Fred Hutchinson Cancer Research Center Al Iskandariyah Fred Hutch Aude Chapuis Imke Meyer
Source: finanznachrichten.de
Cell therapy biotech Affini-T gets $175M; KRAS is lead genomic cancer target
Affini-T Therapeutics is developing new cell therapies for cancer that could overcome limitations of the first generation of cell therapies. The initial genomic cancer targets of the startup are mutations of KRAS and p53, both of which have proven difficult to drug.
Source: medcitynews.com